Medicilon awards Revolution Medicines for partnership excellence
Contract research organization Medicilon has recognized Revolution Medicines with an award for client partnership during a site visit to its Nanhui R&D center.
Medicilon has presented Revolution Medicines, Inc. with an award for excellence in client partnership. The recognition took place during a visit by Revolution Medicines’ senior leadership to Medicilon's research and development facility in Nanhui, China, to discuss ongoing project integration.
Led by Medicilon division president Maosheng Duan, the meeting served to highlight the operational synergy between the two companies. Medicilon provides contract research services, focusing on medicinal chemistry and discovery support to accelerate the drug development timelines of its clients.
For Revolution Medicines, the collaboration is a component of its drug discovery strategy in oncology. By utilizing Medicilon's external research infrastructure, the company aims to optimize its technical output. The award underscores the established working relationship between the two entities as they continue their collaborative research programs.